Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 2.516
Filter
1.
Infectio ; 25(4): 276-283, oct.-dic. 2021. tab, graf
Article in Spanish | LILACS, COLNAL | ID: biblio-1286722

ABSTRACT

Resumen Objetivo: Describir la supervivencia a siete años y los principales factores asociados a esta, en las personas con VIH que fueron atendidas en el sistema de salud colombiano entre 2011 a 2018. Métodos: Análisis de supervivencia de una cohorte de 64 039 personas diagnosticadas con VIH en Colombia. Se aplicó el método de Kaplan-Meier para estimar la probabilidad de supervivencia a partir de la fecha del diagnóstico. Se ajustó un modelo de supervivencia paramétrico flexible de Royston Parmar. Resultados: La estimación de la supervivencia global a 7 años fue de 94,8% (IC 95%: 94,5-95,2). El mayor riesgo de muerte se presentó en los hombres (HR: 1,2; IC 95%: 1,1-1,4; p: 0,010); en personas ≥50 años de edad (HR: 3,1; IC 95%: 1,6-6,3; p: 0,002); en el régimen subsidiado (HR: 2,2; IC 95%: 1,9-2,5; p: <0,001); en la etapa sida (HR: 2,8; IC 95%: 2,1-3,7; p: <0,001); en quienes presentaron la última carga viral detectable (HR: 7,1; IC 95%: 6,0-8,3; p: <0,001); y en quienes mostraron conteo de linfocitos T CD4+ <350 células/μL (HR: 1,9; IC 95%: 1,4-2,4; p: <0,001). Conclusión: La probabilidad de la supervivencia de las personas que viven con VIH aumenta al ser diagnosticados en edades jóvenes, en quienes presenten un recuento de linfocitos T CD4+ ≥350 células/μL, una carga viral indetectable (< 50 copias/mL) y no se encuentren en etapa sida.


Summary Objective: to describe the seven-year survival and predictors of mortality among people with HIV who were treated in the Colombian health system between 2011 and 2018. Methods: 64 039 people diagnosed with HIV in Colombia were included. Kaplan-Meier analysis estimated the probability of survival from the date of diagnosis. A Royston Parmar flexible parametric survival model was fitted. Results: The overall survival at 7 years was 94.8% (95% CI: 94.5-95.2). Survival was related to sex (men, HR: 1.2; 95% CI: 1.1-1.4; p: 0.010); people ≥50 years of age (HR: 3.1; 95% CI: 1.6-6.3; p: 0.002); subsidized regime (HR: 2.2; 95% CI: 1.9-2.5; p: <0.001); AIDS stage (HR: 2.8; 95% CI: 2.1-3.7; p: <0.001); a detectable viral load (HR: 7.1; 95% CI: 6.0-8.3; p: <0.001); and a CD4+ Lymphocyte count <350 cells/μL (HR: 1.9; 95% CI: 1.4-2.4; p: <0.001). Conclusion: The probability of survival of people living with HIV increases when they are diagnosed at a young age, in those with a CD4+ T Lymphocyte count ≥350 cells/μL, an undetectable viral load (<50 copies/mL) and are not in the AIDS stage.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Survival Analysis , Acquired Immunodeficiency Syndrome , Sex , T-Lymphocytes , Probability , HIV , Colombia , Lymphocyte Count , Viral Load , Survivorship
2.
Infectio ; 25(3): 176-181, jul.-set. 2021. tab, graf
Article in English | LILACS, COLNAL | ID: biblio-1250089

ABSTRACT

Abstract Objective: To determine the mortality and survival of COVID-19 cases in Colombia between March and July 2020. Materials and methods: A retrospective cohort study in the Colombian population between March 6 to July 8, 2020, with the data reported to the National Institute of Health. Survival analysis was performed considering the real-time PCR results, died or recovered, the onset of symptoms until the date of death, or the final time of the cohort. The actuarial variation and Long-Rank test were applied for survival. Risk factors were determined by Cox regression. Results: The overall survival rate was 100%, 98%, 97%, and 95% for day 1, 10, 20 and 30, respectively. Differences were found in survival in age, sex, region, and hospitaliza tion time spending (p <0.01), the 30-day survival rate was 96% and 95% for females and males, respectively. The region with the highest survival was Antioquia with 99% and the lower Barranquilla with 93%. The age group with the lowest survival was ≥80 years of age with 60%, and being hospitalized represented a survival rate of 68%. Conclusions: This study is one of the first to estimate survival in the Colombian population diagnosed with COVID-19.


Resumen Objetivo: determinar la mortalidad y supervivencia de casos de COVID-19 en Colombia entre marzo y julio de 2020. Materiales y métodos: Estudio de cohorte retrospectivo en población colombiana entre el 6 de marzo al 8 de julio de 2020, con los datos reportados al Instituto Nacional de Salud. El análisis de supervivencia se realizó considerando los resultados de la PCR en tiempo real, fallecido o recuperado, el inicio de los síntomas hasta la fecha del fallecimiento o el momento final de la cohorte. Para la supervivencia se aplicó la variación actuarial y la prueba de rango largo. Los factores de riesgo se determinaron mediante regresión de Cox. Resultados: La tasa de supervivencia general fue del 100%, 98%, 97% y 95% para los días 1, 10, 20 y 30, respectivamente. Se encontraron diferencias en la su pervivencia en cuanto a edad, sexo, región y tiempo de hospitalización (p <0,01), la tasa de supervivencia a 30 días fue del 96% y 95% para mujeres y hombres, respectivamente. La región con mayor supervivencia fue Antioquia con 99% y la Baja Barranquilla con 93%. El grupo de edad con menor supervivencia fue el ≥80 años con 60%, y la hospitalización representó una tasa de supervivencia del 68%. Conclusiones: Este estudio es uno de los primeros en estimar la supervivencia en la población colombiana diagnosticada con COVID-19.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Aged , Survival Analysis , COVID-19 , Survival Rate , Risk Factors , Cohort Studies , Mortality , Colombia , Survivorship , Methods
3.
Rev. cuba. hematol. inmunol. hemoter ; 37(3): e1505, 2021. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1341404

ABSTRACT

Introducción: Con el protocolo LPM-TOA para el tratamiento de la leucemia promielocítica se obtienen excelentes resultados, se prolonga la sobrevida global y es posible la curación de los enfermos. En la de inducción a la remisión se utilizan dos drogas, una antraciclina y trióxido de arsénico, y en la consolidación los enfermos reciben de nuevo una dosis elevada de arsénico. Objetivo: Evaluar la toxicidad hepática tardía en pacientes con leucemia promielocítica tratados según el protocolo LPM-TOA. Métodos: Se realizó estudio longitudinal prospectivo que incluyó20 pacientes tratados con dicho protocolo, todos con más de dos años de haberlo suspendido. Se revisaron las historias clínicas para evaluar mediante los valores iniciales y evolutivos de las enzimas hepáticas, la función hepática inicial y evolutiva. Se determinó el índice de Ritis para predecir evolución a la cronicidad de existir daño hepático. Resultados: Hombres y mujeres se presentaron con la misma frecuencia y la media para la edad del sexo masculino fue 36,39 y para el femenino 39, con desviación estándar de ±14,02 y ±9,43, respectivamente. La variedad morfológica más frecuente fue la hipergranular, el promedio del índice de Ritis fue de solo 1,006 con desviación estándar de 0,745. Conclusiones: No hubo evidencias clínica ni enzimática de toxicidad hepática tardía en los pacientes estudiados(AU)


Introduction: With the LPM-TOA protocol for the treatment of acute promyelocytic leukemia, excellent results are obtained, overall survival is prolonged and the patients are cured, in the induction to remission two drugs are used, an anthracycline and arsenic trioxide, and in consolidation the patients again receive a high dose of arsenic. Objective: To assess late liver toxicity in patients with promyelocytic leukemia treated according to the PML-TOA protocol. Methods: A prospective longitudinal study was carried out that included 20 patients treated with this protocol, all with more than two years of having suspended treatment. The clinical histories were reviewed and by means of the initial and evolutionary values of liver enzymes, the initial and evolutionary liver function was evaluated and the Ritis index was determined to predict evolution to chronicity if there is liver damage. Results: Men and women presented with the same frequency and the mean age for males was 36.39 and for females it was 39, with a standard deviation of ± 14.02 and ± 9.43 respectively. The most frequent morphological variety was hypergranular, the average Ritis index was only 1.006 with a standard deviation of 0.745. Conclusions: There was no clinical or enzymatic evidence of late liver toxicity in the patients studied(AU)


Subject(s)
Humans , Leukemia, Promyelocytic, Acute/drug therapy , Chemical and Drug Induced Liver Injury/prevention & control , Arsenic Trioxide/toxicity , Survival Analysis , Prospective Studies , Longitudinal Studies
4.
Femina ; 49(7): 444-448, 20210731. tab
Article in Portuguese | LILACS | ID: biblio-1290595

ABSTRACT

A exenteração pélvica pode curar pacientes com câncer de colo do útero com recorrência central após radioterapia e quimioterapia. A avaliação pré-operatória é essencial para excluir doença metastática e evitar cirurgias desnecessárias nesse cenário. O objetivo do presente estudo é avaliar a sobrevida de uma série de casos de pacientes submetidas à exenteração pélvica em clínica privada de Teresina. Este é o resultado parcial de um estudo observacional, retrospectivo, transversal e descritivo, realizado em uma clínica privada especializada no tratamento do câncer em Teresina, PI, Brasil, de junho de 2002 a fevereiro de 2020. Cinco pacientes foram incluídas no estudo, com idades entre 29 e 62 anos. No presente estudo, a sobrevida mediana foi de 44,8 meses. Duas pacientes estão vivas e sem doença com seguimento de 201 e 5 meses, respectivamente.(AU)


Pelvic exenteration can heal patients with cervical cancer with central recurrence after radiotherapy and / or chemotherapy. Preoperative evaluation is essential to exclude metastatic disease and to avoid unnecessary surgery in this scenario. The objective of the present study is to evaluate the survival of a series of cases of patients submitted to pelvic exenteration in a private clinic in Teresina. This is the partial result of an observational, retrospective, cross-sectional and descriptive study, conducted at a private clinic specialized in cancer treatment in Teresina, Brazil, from June 2002 to February 2020. Five patients were included in the study, aged between 29 and 62 years. In the present study, the median survival was 44,8 months. Two patients are alive and without disease with a follow-up of 201 and 5 months, respectively.(AU)


Subject(s)
Humans , Female , Pelvic Exenteration/statistics & numerical data , Survival Analysis , Uterine Cervical Neoplasms/surgery , Neoplasm Recurrence, Local/epidemiology , Survival , Brazil/epidemiology , Cross-Sectional Studies
5.
Oncol. (Guayaquil) ; 31(1): 35-45, Abril 30, 2021.
Article in Spanish | LILACS | ID: biblio-1222457

ABSTRACT

Introducción: El cáncer de próstata constituye la segunda neoplasia más frecuente después del cáncer pulmonar. Es la Primera causa de incidencia de cáncer en la población ecuatoriana, mientras que la mortalidad ocupó el segundo lugar. Enzalutamida retrasa significativamente la necesidad de quimioterapia y la disminución de la calidad de vida. En algunos estudios se ha encontrado disminu-ción del riesgo de muerte y retraso en el inicio de la quimioterapia así como aumento de la supervi-vencia post-quimioterapia con su uso. El objetivo del presente estudio fue caracterizar la evolución clínica de pacientes con cáncer de próstata metastásico resistente a la castración (mCRPC) tratados con enzalutamida. Metodología: Se recopiló información de pacientes atendidos en el servicio de Urología de Solca - Guayas del año 2013 al 2019. Se incluyeron todos los casos con cáncer de próstata metastásico resistente a la castración. Resultados: El promedio de edad fue de 77.3 ± 9.9 años. El tamaño inicial prostático fue de 59.9 ± 43.7 g. Los síntomas con mayor frecuencia registrados fueron: hematuria 18,8%, disminución del chorro miccional 18.8%, polaquiuria y poliuria con 14.6% cada uno. . La supervivencia global fue del 80% en los casos tratados con enzalutamida. Ninguna muerte estuvo asociada con el uso de enzalu-tamida. En el 66,6% se registraron eventos adversos. De todos los eventos adversos registrados el 82.3% fueron leves. Conclusión: La supervivencia global en el grupo estudiado estuvo acorde a los reportes de supervivencia en pacientes tratados con enzalutamida. La terapia con enzalutamida fue bien tolerada.


Introduction: Prostate cancer is the second most common neoplasm after lung cancer. It is the leading cause of cancer incidence in the Ecuadorian population, while mortality ranked second. En-zalutamide significantly delays the need for chemotherapy and decreases the quality of life. Some studies have found a decrease in the risk of death and a delay in the start of chemotherapy, as well as an increase in post-chemotherapy survival with its use. The aim of this study was to characterize the clinical course of patients with metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide. Methodology: Information was collected from patients treated in the Urology services of Solca - Guayas from 2013 to 2019. All cases with metastatic castration-resistant prostate cancer were in-cluded. Results: The mean age was 77.3 ± 9.9 years. The initial prostate size was 59.9 ± 43.7 g. The symp-toms with the highest frequency recorded were: hematuria 18.8%, decreased voiding stream 18.8%, frequency and polyuria with 14.6% each. Overall survival was 80% in the cases treated with enzalu-tamide. No deaths were associated with the use of enzalutamide. Adverse events were recorded in 66.6%. Of all the adverse events recorded, 82.3% were mild. Conclusion: The overall survival in the studied group was consistent with the survival reports in patients treated with enzalutamide. Enzalutamide therapy was well tolerated.


Subject(s)
Prostatic Neoplasms, Castration-Resistant , Androgen Antagonists , Neoplasm Metastasis , Prostatic Neoplasms , Survival Analysis
6.
Arch. med ; 21(1): 35-44, 2021/01/03.
Article in Spanish | LILACS | ID: biblio-1148355

ABSTRACT

Objetivo: identificar las variables clínicas que impactan en la mortalidad de los pacientes con falla cardiaca implantados con desfibrilador automático. La terapia con cardiodesfibrilador implantable busca prevenir la muerte súbita cardiaca por arritmias malignas colapsantes. Material y métodos: estudio de cohorte retrospectiva. Se incluyó a pacientes con implante de desfibrilador entre los años 2010-2012, con dispositivo funcional, historia clínica y disponibilidad de seguimiento hasta el primer trimestre del 2014. Resultados: un total de 30 pacientes fueron incluidos, con una supervivencia del 77% a los cuatro años de seguimiento. El 82,7% de los pacientes presentó cardiopatía isquémica y el promedio de la fracción de eyección ventricular izquierda fue 27,8 ± 6,3. El tiempo promedio de uso del desfibrilador fue de 2,1 años, la tasa de peligro mayor reportada fue del 6% para los días 759 y 760. Se encontró una asociación entre una duración del QRS mayor a 120 ms (HR= 7,7, IC 90%= 1,77- 33,6; p=0,022), fibrilación auricular (HR= 4,2, IC 90%=1,13-15,68; p=0,072) y el uso de beta-bloqueadores (HR= 0,15, IC 90%= 0,03 ­ 0,64; p=0,031) con el tiempo de supervivencia. Discusión: la prevención de muerte súbita está condicionada por la optimización farmacológica, así como las anomalías estructurales y de la conducción eléctrica, por lo cual se debe aumentar el seguimiento en estos casos y el ajuste de la terapia farmacológica. Conclusiones: el uso de beta bloqueadores en pacientes con falla cardiaca con fibrilación auricular y duración del QRS mayor de 120 ms es un factor protector..Au


Objective: to identify the clinical variables that impact on the mortality of patients with heart failure implanted with cardioverter defibrillator. Implantable cardioverter defibrillator therapy seeks to prevent sudden cardiac death by collapsing malignant arrhythmias. Material y methods: retrospective cohort study. Patients with a defibrillator implant from the year 2010 to the year 2012 were included, with functional device, clinical history and availability of follow-up until the first quarter of 2014. Results: a total of 30 patients were included, with a 77% survival at four years of follow-up. 82.7% of the patients presented with ischemic heart disease and the mean left ventricular ejection fraction was 27.8 ± 6.3. The mean time of use of the defibrillator was 2.1 years, the reported mayor danger rate was 6% for days 759 and 760. An association was found between a QRS mayor duration at 120 ms (HR = 7.7, 90% CI = 1.77-33.6, p = 0.022), atrial fibrillation (HR = 4.2, 90% CI = 1.13-15.68, p = 0.072), and beta- blockers (HR = 0.15, 90% CI = 0.03-0.64, p = 0.031) with survival time. Discussion: the prevention of death is conditioned by pharmacological optimization, as well as structural and electrical conduction anomalies, so the monitoring and adjustment of pharmacological therapy should be increased. Conclusions: the use of beta-blockers in patients with atrial fibrillation and QRS duration greater than 120 ms is a protective factor..Au


Subject(s)
Humans , Survival Analysis , Defibrillators, Implantable
7.
Rev. patol. trop ; 50(3)2021. ilus
Article in English | LILACS | ID: biblio-1292484

ABSTRACT

Tuberculosis is the leading cause of death amongst adults with human immunodeficiency virus (HIV) infection. The lifetime risk of tuberculosis disease for a person with latent infection is estimated at 5-10% with most cases occurring within five years of initial infection. The World Health Organization recommends isoniazid preventive therapy (IPT) for latent tuberculosis treatment, amongst other strategies. The aim was to assess tuberculosis incidence, survival (free of tuberculosis) and associated factors in HIV-positive patients. IPT was offered to participants with a positive (≥5mm) tuberculin skin test. Participants were followed from February 2003-December 2016. Kaplan-Meier was used for survival analysis. Variables with p-value ≤ 0.2 in the univariate analysis entered into the multivariate Cox-Model, keeping those with p-value ≤ 0.05. The 95% confidence interval of incidence of tuberculosis was estimated using Poisson distribution. One hundred nineteen patients completed the IPT and were followed for a median duration of 110.7 months (IQR 93.1-121.0). The probability of developing tuberculosis (10 years post-IPT) was 5.4%. Tuberculosis incidence was 0.58/100 patient/years (CI 95% 0.213-1.264). IPT over 6 months provided long-term protection against tuberculosis. AIDS-defining illness was the only statistically significant variable (HR=5.67) in the multivariate model.


Subject(s)
Humans , Survival Analysis , HIV , Latent Tuberculosis , Isoniazid
8.
Rev. latinoam. enferm. (Online) ; 29: e3412, 2021. tab, graf
Article in English | LILACS, BDENF | ID: biblio-1289787

ABSTRACT

Objective: to identify breastfeeding patterns, survival of exclusive breastfeeding and factors associated with its interruption, in the first six months of life of babies seen by Lactation Consulting. Method: a prospective cohort, with 231 mother-babies in a Baby-Friendly Hospital. An initial questionnaire was applied after 24 hours of birth, after consulting, as well as a follow-up questionnaire, applied by telephone at 15, 30, 60, 120 and 180 days, with sociodemographic and obstetric variables, maternal habits, father's schooling, birth data and baby feeding. Survival Analysis was carried out. Results: at 180 days of age, exclusive breastfeeding was 12.7% and the probability was 19.6% in the analysis of the survival curve. The factors associated with its interruption were smoking during pregnancy (HR 1.66; CI 1.05 - 2.61), age ≥ 35 years old (HR 1.73; CI 1.03 - 2.90), difficulty in breastfeeding after hospital discharge (HR 2.09; CI 1.29 - 3.41), search for professional assistance (HR 2.45; CI 1.69 - 3.54) and use of a pacifier (HR 1.76; IC 1.21 - 2.58). Conclusion: lactation consultancy contributed to the improvement of the exclusive breastfeeding rates, although there are opportunities for advances.


Objetivo: identificar padrões de amamentação, sobrevida do aleitamento materno exclusivo e fatores associados à sua interrupção, nos seis primeiros meses de vida de bebês atendidos por Consultoria em Lactação. Método: coorte prospectiva, com 231 mãe-bebê em Hospital Amigo da Criança. Utilizou-se questionário inicial aplicado após 24 horas do nascimento, depois da consultoria, e de seguimento, aplicado por telefone aos 15, 30, 60, 120 e 180 dias, com variáveis sociodemográficas, obstétricas, hábitos maternos, escolaridade paterna, dados do nascimento e alimentação do bebê. Procedeu-se à Análise de Sobrevivência. Resultados: aos 180 dias de vida, o aleitamento materno exclusivo foi 12,7% e probabilidade de 19,6% na análise da curva de sobrevivência. Os fatores associados à sua interrupção foram tabagismo na gestação (HR 1,66; IC 1,05 - 2,61), idade ≥ 35 anos (HR 1,73; IC 1,03 - 2,90), dificuldade na amamentação pós-alta hospitalar (HR 2,09; IC 1,29 - 3,41), busca por auxílio profissional (HR 2,45; IC 1,69 - 3,54) e uso de chupeta (HR 1,76; IC 1,21 - 2,58). Conclusão: a consultoria em lactação contribuiu para melhoria das taxas de aleitamento materno exclusivo, embora existam oportunidades de avanços.


Objetivo: identificar patrones de lactancia materna, supervivencia de la lactancia materna exclusiva y factores asociados a su interrupción, en los primeros seis meses de vida de los bebés atendidos por Consultoría de Lactancia. Método: cohorte prospectiva, con 231 madres-bebés en el Hospital Amigo del Niño. Se aplicó un cuestionario inicial a las 24 horas del nacimiento, previa consultoría, y de seguimiento, aplicado por teléfono a los 15, 30, 60, 120 y 180 días, con variables sociodemográficas, obstétricas, hábitos maternos, educación del padre, datos de nacimiento y alimentación del bebé. Se llevó a cabo un Análisis de Supervivencia. Resultados: a los 180 días de vida, la lactancia materna exclusiva fue del 12,7% y la probabilidad del 19,6% en el análisis de la curva de supervivencia. Los factores asociados a su interrupción fueron el tabaquismo en la gestación (HR 1,66; IC 1,05 - 2,61), edad ≥ 35 años (HR 1,73; IC 1,03 - 2,90), dificultad para amamantar después del alta hospitalaria (HR 2,09; IC 1,29 - 3,41), búsqueda de asistencia profesional (HR 2,45; IC 1,69 - 3,54) y uso de chupete (HR 1,76; IC 1, 21-2,58). Conclusión: la consultoría en lactancia contribuyó a la mejora de las tasas de lactancia materna exclusiva, aunque existen oportunidades de avances.


Subject(s)
Humans , Female , Infant , Adult , Breast Feeding , Lactation , Survival Analysis , Cohort Studies , Consultants , Educational Status , Nursing Care
9.
Rev. bras. cancerol ; 67(1): e-01841, 2021.
Article in Portuguese | LILACS | ID: biblio-1146871

ABSTRACT

Introdução: O tromboembolismo venoso é uma condição potencialmente fatal e frequente no paciente oncológico. Muitas vezes, a anticoagulação é inviável, e a colocação do filtro de veia cava (FVC) torna-se uma opção. A indicação clínica, entretanto, é controversa e gera alto custo. Objetivo: Descrever as características demográficas, clínicas e epidemiológicas dos pacientes com colocação de FVC e seu impacto na sobrevida global. Método: Estudo de coorte retrospectiva com pacientes em tratamento oncológico no INCA, que tiveram FVC implantado de janeiro/2015 até abril/2017. Na análise de sobrevida global em cinco anos, foram considerados o tempo entre o diagnóstico de câncer e o óbito por qualquer causa. Realizaram-se análise descritiva, estimativas de sobrevida (Kaplan-Meier) e regressão de Cox. Resultados: Foram incluídos 74 pacientes com média de idade 54 (+-15) anos. Em sua maioria, apresentavam tumores ginecológicos (52,7%) e digestivos (20,3%). O tempo mediano entre o diagnóstico de câncer e a colocação do FVC foi de 3,48 meses (0-203). No seguimento, foram observados 40 óbitos (54,1%) com mediana de tempo de 25 meses (IC 95%; 1,76-47,32). Na análise ajustada, verificou-se risco 5,63 vezes maior de morrer nos pacientes com colocação do FVC em até seis meses após o diagnóstico de câncer (HR=4,99; IC 95%; 2,20-11,33; p<0,001), e risco 2,47 vezes maior entre aqueles que não fizeram no pré-operatório (HR=2,47; IC 95%; 1,08-5,66; p=0,032). Conclusão: A colocação do FVC foi realizada com maior frequência em pacientes com tumores ginecológicos e em até seis meses após o diagnóstico de câncer foi associada a maior risco de óbito.


Introduction: Venous thromboembolism is a potentially fatal condition and frequent in oncologic patients. Quite often full anticoagulation is unfeasible, and placement of an inferior vena cava (IVC) filter becomes an option. Clinical indication, however, is controversial and expensive. Objective: To describe the demographic, clinical and epidemiological characteristics of oncologic patients submitted to IVC filter placement and their impact on global survival. Method: Retrospective cohort study with patients undergoing cancer treatment at INCA submitted to IVC filter placement from January 2015 to April 2017. Time between cancer diagnoses and death from any cause was considered for the analysis of the global 5-years survival. Descriptive analysis, survival estimates (Kaplan-Meyer) and Cox regression were performed. Results: 74 patients with a mean age of 54 (+15) years were included. Most of them had gynecological (52.7%) and digestive (20.3%) tumors. The median time between cancer diagnosis and IVC filter placement was 3.48 months (0-203). In the follow-up, 40 deaths (54.1%) were observed with a median time of 25 months (95% CI; 1.76 to 47.32). In the adjusted analysis, 5.63 times greater risk of death was verified in patients with IVC filter placement within six months after cancer diagnosis (HR=4.99; 95% CI; 2.20-11.33; p<0.001), and 2.47 times greater risk among those who did not do it at pre-operation (HR=2.47; 95% CI; 1.08-5.66; p=0.032). Conclusion: IVC filter placement was performed more frequently in patients with gynecological tumors and in until six months after cancer diagnosis was associated with increased risk of death.


Introducción: El tromboembolismo venoso es una afección potencialmente mortal y frecuente en pacientes con cáncer. La anticoagulación a menudo no es factible, y la colocación de un filtro de vena cava (FVC) se convierte en una opción. Sin embargo, las indicaciones clínicas son controvertidas y generan un alto costo. Objetivo: Describir las características demográficas, clínicas y epidemiológicas de los pacientes con colocación de CVF y su impacto en la supervivencia general. Método: Estudio de cohorte retrospectivo de pacientes sometidos a tratamiento contra el cáncer en INCA a quienes se les implantó FVC entre enero de 2015 y abril de 2017. En el análisis de la supervivencia general a cinco años, el tiempo transcurrido entre el diagnóstico de cáncer y la muerte cualquier causa Se realizó un análisis descriptivo, estimaciones de supervivencia (Kaplan-Meier) y regresión de Cox. Resultados: Se incluyeron 74 pacientes con una edad media de 54 (+-15) años. La mayoría de ellos tenían tumores ginecológicos (52,7%) y digestivos (20,3%). La mediana del tiempo entre el diagnóstico de cáncer y la colocación de FVC fue de 3,48 meses (0-203). En el período de seguimiento, se observaron 40 muertes (54,1%) con una mediana de tiempo de 25 meses (IC 95%: 1,76 a 47,32). En el análisis ajustado, se observó un riesgo de muerte 5,63 veces mayor en pacientes con colocación de FVC dentro de los seis meses posteriores al diagnóstico de cáncer (HR=4,99; IC 95%: 2,20-11,33; p<0,001) y 2,47 veces mayor riesgo entre aquellos que no lo hicieron antes de la operación (HR=2,47; IC 95%; 1,08-5,66; p=0,032). Conclusión: La colocación de FVC se realizó con mayor frecuencia en pacientes con tumores ginecológicos. La colocación de FVC dentro de los seis meses posteriores al diagnóstico de cáncer se asoció con un mayor riesgo de muerte.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Vena Cava Filters/adverse effects , Venous Thromboembolism/mortality , Neoplasms/mortality , Prognosis , Time Factors , Survival Analysis , Retrospective Studies , Venous Thromboembolism/surgery , Venous Thromboembolism/complications , Genital Neoplasms, Female/complications , Genital Neoplasms, Female/mortality , Neoplasms/complications
10.
Rev. bras. cancerol ; 67(1): e-16967, 2021.
Article in Portuguese | LILACS | ID: biblio-1147265

ABSTRACT

Introdução: A neoplasia maligna de pâncreas configura uma das neoplasias de maior mortalidade em todo o mundo, quase sempre atrelada a um prognóstico sombrio, principalmente quando associada à disseminação linfática e para órgãos distantes. Objetivo: Avaliar a sobrevida global em pacientes com adenocarcinoma de pâncreas atendidos em um centro especializado em oncologia. Método: No período de janeiro de 2011 a dezembro de 2014, foram avaliados retrospectivamente 71 prontuários. Os dados foram analisados pelo software STATA versão 14, utilizando análise de Kaplan-Meier e de regressão de Cox. O intervalo de confiança utilizado foi de 95% e considerado significante p<0,05. Foram preservados os princípios éticos e da confidencialidade. Resultados: Houve predomínio do sexo masculino, raça parda e com idade superior a 61 anos ao diagnóstico. Quanto às características clínicas, 87,8% dos tumores estavam localizados em cabeça de pâncreas. A dor abdominal (92,7%) foi o sintoma mais frequente, seguida de perda progressiva de peso (79,3%) e icterícia (57,3%). A taxa de sobrevida em três meses de acompanhamento foi de 48,4%. Conclusão: O estudo evidencia que o câncer de pâncreas tem uma repercussão extremamente negativa, visto que a maioria dos pacientes recebe o diagnóstico em estágios avançados da doença, dificultando a possibilidade de tratamento curativo.


Introduction: Pancreatic malignant neoplasia represents one of the highest mortality neoplasms worldwide, almost always associated to a dismal prognosis, especially when associated with lymphatic spread and to distant organs. Objective: To assess the global survival in patients with pancreatic adenocarcinoma treated at a specialized oncology center. Method: From January 2011 to December 2014, 71 medical records were retrospectively evaluated. The data were analyzed using the STATA software version 14, using the Kaplan-Meier curve and the Cox regression. The confidence interval used was 95% (p<0.05). Ethical and confidentiality principles have been secured. Results: There was predominance of males, mixed race and over 61 years of age at diagnosis. As for the clinical characteristics, 87.8% of the tumors were located in the head of the pancreas. Abdominal pain (92.7%) was the most frequent symptom, followed by progressive weight loss (79.3%) and jaundice (57.3%). The three-month follow-up survival rate was 48.4%. Conclusion: The study shows that pancreatic cancer has an extremely negative repercussion, since most patients are diagnosed in advanced stages of the disease, hindering the possibility of curative treatment.


Introducción: La neoplasia maligna pancreática representa una de las neoplasias de mortalidad más altas del mundo, casi siempre vinculada a un pronóstico sombrío, especialmente cuando se asocia con diseminación linfática y órganos distantes. Objetivo: Evaluar la supervivencia global en pacientes con adenocarcinoma pancreático tratados en un centro de oncología especializado. Método: Desde enero de 2011 hasta diciembre de 2014, se evaluaron retrospectivamente 71 registros médicos. Los datos se analizaron utilizando el software STATA versión 14, utilizando la curva de Kaplan-Meier y la regresión de Cox. El intervalo de confianza utilizado fue del 95% (p<0,05). Se han preservado los principios éticos y de confidencialidad. Resultados: Predominó el sexo masculino, la raza mixta y los mayores de 61 años en el momento del diagnóstico. En cuanto a las características clínicas, el 87,8% de los tumores se ubicaron en la cabeza del páncreas. El dolor abdominal (92,7%) fue el síntoma más frecuente, seguido de pérdida progresiva de peso (79,3%) e ictericia (57,3%). La tasa de supervivencia de seguimiento a los tres meses fue del 48,4%. Conclusión: El estudio muestra que el cáncer de páncreas tiene un impacto extremadamente negativo, ya que la mayoría de los pacientes reciben el diagnóstico en etapas avanzadas, obstaculizando la posibilidad de tratamiento curativo.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Pancreatic Neoplasms/epidemiology , Survival Analysis , Delayed Diagnosis
11.
Article in English | LILACS | ID: biblio-1342994

ABSTRACT

Objective: this study aimed to evaluate long-term survival and prognostic factors in patients with oral squamous cell carcinoma (OSCC) in an economically poor region of Brazil. Methods: the data were obtained from analysis of medical and mortality records of 210 patients with OSCC treated at an oncology hospital providing services to the Brazilian Unified National Health System in a State of northeastern Brazil between January 2006 and December 2008. Sociodemographic and clinical information, treatment performed, recurrence and evolution were collected. Survival curves were estimated by the Kaplan-Meier method and the log rank and Cox regression tests were used to compare the curves. Results: the median survival in the study period was 47.4 months (95% CI = 38.2 - 56.7). The overall survival rates at 5 and 10 years were 29% and 19.8%, respectivelly. Individuals over 60 years of age (HR = 1.70; 95% CI = 1.06 - 2.73), presence of regional metastasis (HR = 2.51; 95% CI = 1.55 - 4.08), presence of recurrence (HR = 3.18; 95% CI = 1.88 - 5.39) and no surgical treatment (HR = 2.10; 95% CI = 1.31 - 3.35) had a worse prognosis. Conclusions: advanced age, presence of regional metastasis, tumor recurrence and non-surgical treatment predict poorer survival in patients diagnosed with OSCC.


Objetivo: este estudo objetivou avaliar a sobrevida a longo prazo e fatores prognósticos de pacientes com carcinoma espinocelular bucal em uma região pouco desenvolvida economicamente do Brasil. Métodos: os dados foram obtidos a partir da análise de registros médicos de 210 pacientes com carcinoma espinocelular bucal tratados em um hospital especializado em oncologia que presta serviços ao Sistema Único de Saúde em um estado do Nordeste brasileiro entre janeiro de 2006 e dezembro de 2008. Informações clínicas, sociodemográficas e referentes aos tratamentos realizados, recidivas e evoluções foram coletadas. As curvas de sobrevida foram estimadas pelo método de Kaplan-Meier, sendo utilizado o teste de Log-rank para comparar as curvas. Resultados: a sobrevida média no estudo foi de 47.4 meses (95% IC = 38.2 - 56.7). As taxas de sobrevida global em 5 e 10 anos foram de 29% e 19.8%, respectivamente. Indivíduos com idade superior a 60 anos (RR = 1.70; 95% IC = 1.06 - 2.73), que apresentaram metástases regionais (RR = 2.51; 95% IC = 1.55 - 4.08), recidivas tumorais (RR = 3.18; 95% IC = 1.88 - 5.39) e que foram tratados apenas não cirurgicamente (RR = 2.10; 95% IC = 1.31 - 3.35) tiveram pior prognóstico. Conclusões: idade avançada, presença de metástases regionais, recidivas tumorais e tratamento apenas não cirúrgico foram preditores de pior sobrevida em pacientes diagnosticados com carcinoma espinocelular bucal.


Subject(s)
Humans , Male , Female , Carcinoma, Squamous Cell , Prognosis , Mouth Neoplasms , Survival Analysis , Oral Medicine
12.
Article in Chinese | WPRIM | ID: wpr-880111

ABSTRACT

OBJECTIVE@#To explore the clinical features, prognosis and survival of patients with IgD multiple myeloma (MM).@*METHODS@#The clinical data of 20 patients with IgD MM was analyzed retrospectively. The prognostic factors and survival analysis was carried out. We summarized their clinical characteristics. The survival analysis was carried out by Kaplan-Meier method, and the prognostic factor were analyzed by using log-rank test for single factor analysis of observation index. Variables of P<0.15 in single factor analysis were enrolled in multifactor cox regression analysis.@*RESULTS@#IgD MM patients accounted for 4.3% of all MM patients in the same period, among which 80% were male, the median age of patients was 57.5(35-77) years old, 90% of the patients belongs to λ light chain type. At the time of diagnosis, 18 patients (90%) were in DS-Ⅲ stages, while 10 patients were in ISS-Ⅲ stage. The first clinical manifestations were fatigue, bone pain, kidney function impairment, anemia (Hb<100 g/L) in 14 cases (70%), 12 cases (60%) with osteolytic bone destruction≥3, combined with renal impairment in 8 cases (40%), and elevated blood calcium in 11 cases (51.4%). In only 5 patients the ratio of albumin to globntin was inverted, hypoalbuminemia accounted for 40%, and globulin increase accounted for only 15%. FISH results showed that the positive rate of 1q21 amplification (50%) was the highest, and it was easy to occur at the same time as other cytogenetic abnormalities. Extramedullary infiltration occurred in 4 cases (20%). The analysis of prognostic factors showed that only the increase of lactate dehydrogenase (LDH) level was an independent poor prognostic factor for IgD MM patients. Extramedullary infiltration and various cytogenetic abnormalities were found in 2 IgD MM patients with primary drug resistance, suggesting that extramedullary infiltration and various cytogenetic abnormalities may be prognostic factors, but the difference was not statistically significant, Which maybe related to the small sample size. All 20 patients were treated with bortezomib-containing regimen, of which 19 patients were evaluated, 17 patients (89.4%) showed effective, including CR+VGPR (52.6%), PR (31.5%), MR (5.3%), 2 patients primary drug resistance. The median PFS and OS was 9.5 and 10.5 months, respectively.@*CONCLUSION@#IgD MM is a rare and invasive disease. Increased LDH is an independent prognostic factor. Bortizomib-containing regimen can improve the prognosis of IgD MM patients.


Subject(s)
Aged , Disease-Free Survival , Female , Humans , Immunoglobulin D , Male , Middle Aged , Multiple Myeloma , Prognosis , Retrospective Studies , Survival Analysis , Treatment Outcome
13.
Cambios rev. méd ; 19(2): 6-11, 2020-12-29. ^eVIDEO: https://youtu.be/kIDnpec0mnkilus.
Article in Spanish | LILACS | ID: biblio-1179137

ABSTRACT

INTRODUCCIÓN. El primer trasplante hepático en el mundo se realizó en Estados Unidos en 1963 por Thomas Starzl, hasta la década de los 90 la supervivencia al año fue de 73% y a los 5 años de 64%, según diferentes series que abarcaron más de 1 000 trasplantes realizados hasta 1989. El Ecuador requiere de estas estadísticas. El Hospital de Especialidades Carlos Andrade Marín inició la actividad del programa en mayo del 2016. OBJETIVO. Conocer la supervivencia global de los pacientes sometidos a trasplante hepático. MATERIALES Y MÉTODOS. Estudio observacional, descriptivo, con una población igual a la muestra de 62 datos de Historias Clínicas del Programa de Trasplante Hepático en la Unidad Técnica de Trasplante del Hospital de Especialidades Carlos Andrade Marín en el período mayo 2016 a diciembre 2019. Criterios de inclusión: pacientes so-metidos a trasplante hepático, con seguimiento durante 43 meses. La información se obtuvo de la base de datos del sistema AS400; se analizaron en el programa estadístico International Business Machines Statistical Package for the Social Sciences, versión 23.0. RESULTADOS. La supervi-vencia global a los 12 meses fue 72% (17; 62) y a los 43 meses fue 69% (19; 62). DISCUSIÓN. Se evidenció similares resultados descritos de supervivencia en centros con actividad en periodos cortos, menor a 5 años. CONCLUSIÓN. Se pudo conocer la supervivencia global de los pacientes trasplantados del hospital, cuya expectativa motiva a potenciar el programa para mejorar la calidad de vida de los pacientes candidatos a trasplante.


INTRODUCTION. The first liver transplant in the world was performed in the United States in 1963 by Thomas Starzl, until the 90s the survival at one year was 73% and at 5 years it was 64%, accor-ding to different series that included more than 1 000 transplants carried out until 1989. Ecuador re-quires these statistics. The Carlos Andrade Marín Specialty Hospital began program activity in May 2016. OBJECTIVE. To know the overall survival of patients undergoing liver transplantation. MATE-RIALS AND METHODS. Observational, descriptive study, with a population equal to the sample of 62 data from the Medical Records of the Liver Transplant Program in the Technical Transplant Unit of the Carlos Andrade Marín Specialty Hospital in the period May 2016 to December 2019. Inclusion criteria: patients submitted to liver transplantation, with follow-up for 43 months. The information was obtained from the AS400 system database; were analyzed in the statistical program Internatio-nal Business Machines Statistical Package for the Social Sciences, version 23.0. RESULTS. Ove-rall survival at 12 months was 72% (17; 62) and at 43 months it was 69% (19; 62). DISCUSSION. Similar survival results described were evidenced in centers with activity in short periods, less than 5 years. CONCLUSION. It was possible to know the overall survival of the transplanted patients at the hospital, whose expectation motivates us to promote the program to improve the quality of life of the transplant candidates.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Transplantation , Survival Analysis , Liver Transplantation , Hemochromatosis , Liver , Liver Cirrhosis , Quality of Life , Survival , Tissue Donors , Medical Records , Aftercare , Survivorship
15.
Med. infant ; 27(2): 107-112, Diciembre 2020. ilus, Tab
Article in Spanish | LILACS, BINACIS, UNISALUD | ID: biblio-1148102

ABSTRACT

La injuria renal aguda (IRA) se caracteriza por un abrupto deterioro de la función renal asociado a lteraciones hidroelectrolíticas y metabólicas. La misma es frecuente en la unidad de cuidados intensivos (UCI) pediátricos y tiene un impacto significativo en la morbilidad y mortalidad. Las principales indicaciones de terapia de reemplazo renal (TRR) incluyen la corrección de los trastornos metabólicos y el manejo de la sobrecarga de fluidos. Varios modos de TRR pueden ser utilizadas en la UCI: hemodiálisis intermitente, diálisis peritoneal y las terapias de reemplazo renal continuas (TRRC). Las terapias de reemplazo renal continuas han ganado un rol preponderante en Cuidados Críticos ya que posibilitan dializar a pacientes hemodinámicamente inestables. Del total de pacientes admitidos en la UCI (n:1506) desde enero 2012 hasta diciembre 2018, requirieron TRRC el 6,7% (n: 102). La mortalidad predicha por el Score PIM3 fue de 19,53%, la mediana de edad en meses fue de 60 (RIC 25-75: 12-144), no hubo diferencias en cuanto al sexo. Los diagnósticos más frecuentes fueron trasplantados de órganos sólidos 33%, seguidos de trasplante de células progenitoras hematopoyéticas (TCPH) el 26%. La mediana de los días de internación fue de 16 (RIC 25-75: 7-29) y de días de requerimiento de una TRRC 5 (RIC 25-75 3-9). La técnica dialítica más utilizada fue CVVHD, en el 87% de los pacientes. La mortalidad global fue del 75%, presentando los pacientes con TCPH mayor mortalidad con respecto a otros diagnósticos. Se debe reconocer y categorizar precozmente a los pacientes con mayor riesgo de desarrollar IRA y aplicar medidas de nefroprotección para mejorar su sobrevida (AU)


Acute renal injury (IRA) is characterized by sudden deterioration of kidney function associated with hydroelectrolytic and metabolic disturbances. IRA is common in the pediatric intensive care unit (ICU) and has a significant impact on morbidity and mortality. The main indications for renal replacement therapy (RRT) include correction of the metabolic disorders and management of fluid overload. Different types of RRT may be used in the ICU: intermittent hemodialysis, peritoneal dialysis, and continuous renal replacement therapies (CRRT). Continuous renal replacement therapies have gained a major role in critical care as they allow for dialysis in hemodynamically unstable patients. Of all patients admitted to the ICU (n:1506) between January 2012 and December 2018, 6.7% required CRRT (n: 102). Predicted mortality rate according to the PIM3 score was 19.53%. Median age was 60 months (IQR 25-75: 12-144). No differences in sex were observed. The most common diagnoses were solid organ transplantation in 33%, followed by hematopoietic stem cell transplantation (HSCT) in 26%. Median length of hospital stay was 16 days (IQR 25-75: 7-29) and median days on CTTT was 5 (IQR 25-75 3-9). The most common dialysis technique was CVVHD, used in 87% of the patients. Overall mortality rate was 75%, with a higher mortality in HSCT patients compared to others. Patients at a higher risk of developing IRA should be timely recognized and categorized and nephroprotective measures should be started early to improve survival (AU)


Subject(s)
Humans , Infant , Child, Preschool , Child , Water-Electrolyte Imbalance , Intensive Care Units, Pediatric , Immunocompromised Host , Critical Illness , Acute Kidney Injury/therapy , Continuous Renal Replacement Therapy , Survival Analysis , Retrospective Studies , Treatment Outcome
16.
Rev. cuba. pediatr ; 92(4): e973, oct.-dic. 2020. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1144518

ABSTRACT

Introducción: El síndrome de dificultad respiratoria aguda es una enfermedad que cursa con hipoxemia severa, poco frecuente en las unidades de cuidados intensivos pediátricos, pero con elevada mortalidad. Objetivo: Determinar la relación entre variables demográficas y clínicas con la duración de la ventilación mecánica y la supervivencia en niños con síndrome de dificultad respiratoria aguda. Métodos: Estudio retrospectivo de los pacientes ingresados en 15 unidades de cuidados intensivos pediátricos, con diagnóstico de síndrome de dificultad respiratoria aguda. Se evaluaron variables demográficas, las formas clínicas del síndrome de dificultad respiratoria aguda, duración de la ventilación mecánica y la supervivencia. Las variables cualitativas se expresaron en valores absolutos y porcentajes, las variables cuantitativas se analizaron con la prueba ji-cuadrada de Pearson y comparación de medias. Resultados: Se registraron 282 pacientes, de ellos 63,7 por ciento menores de seis años, el 54,4 por ciento del sexo masculino y el 51,1 por ciento de piel blanca. Las formas clínicas pulmonares prevalecieron (58,1 por ciento) y se correlacionaron (p= 0,022) con la supervivencia, la mediana de la duración de la ventilación mecánica fue de 10 días. Existió relación (p= 0,000) entre la duración de la ventilación y la mortalidad. Se registró una mortalidad global de 40,78 por ciento, (n= 115). Conclusiones: El síndrome de dificultad respiratoria aguda tiene mayor incidencia en los menores de seis años y en las formas clínicas pulmonares que se relacionan con una mayor supervivencia, la cual se eleva en la medida que aumentan los días de ventilación mecánica(AU)


ABSTRACT Introduction: The acute respiratory distress syndrome is a disease that evolves with severe hypoxemia, and it is not frequent in pediatric intensive care units, but it has high mortality rates. Objective: To determine the relation between demographic and clinical variables with the mechanical ventilation and survival in children with acute respiratory distress syndrome. Methods: Retrospective study in patients admitted in 15 pediatric intensive care units with diagnosis of acute respiratory distress syndrome. There was an assessment of the demographic variables, the clinical forms of this syndrome, the duration of mechanical ventilation and the survival rates. Qualitative variables were presented in absolute values and percentages, and were analyzed with the Pearson´s ji-square test and means comparison. Results: 282 patients were recorded, 63.7 percent of them were under 6 years old, 54.4 percent were males and 51.1 percent were white. Pulmonary clinical forms prevailed (58,1 percent) and were correlated (p= 0,022) with the survival rates, and the mean of mechanical ventilation´s duration was of 10 days. There was relation (p= 0,000) between the duration of ventilation and mortality. It was recorded a total mortality of 40.78 percent (n= 115). Conclusions: Acute respiratory distress syndrome has higher incidence in children under 6 years and in the pulmonary clinical forms that are related with a higher survival, which increases in the same way that mechanical ventilation´s amount of days do(AU)


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Respiration, Artificial/mortality , Respiratory Distress Syndrome/epidemiology , Intensive Care Units, Pediatric , Child Health , Survival Analysis , Retrospective Studies
17.
J. coloproctol. (Rio J., Impr.) ; 40(4): 315-320, Oct.-Dec. 2020. tab, graf
Article in English | LILACS | ID: biblio-1143170

ABSTRACT

ABSTRACT Background Current threshold for minimum lymph node harvest may not be adequate for appropriate staging in colon cancer and newer surgical techniques may allow more lymph nodes to be harvested. The aim of this study was to examine the prognostic role of harvesting and examining lymph nodes higher in number than the recommended threshold (≥12), in patients with colon cancer. Methods This retrospective study included 179 patients that underwent open colon resection for adenocarcinoma of the colon. A D3 resection with high vascular ligation was made so that large number of lymph nodes was removed in most patients. Differences in overall survival between below and above three cutoff points (≥18, ≥24, ≥40) were estimated. Results During median 33 months of follow-up, 45 patients died and mean overall survival was 108.7 ± 5.6 months (95% CI, 97.7-119.7). The mean number of lymph nodes harvested and examined was 44.0 ± 25.7 (median 38; range, 7-150). No significant effect was found for three different cut-off values (≥18, ≥24, or ≥40 nodes) on mean overall survival (p > 0.05 for all comparisons). The same was true for the whole study population as well as for N0 (N negative) and N1-2 (N positive) patient subgroups, when they are analyzed separately. Conclusions Our findings do not support the survival benefit of substantially higher number of lymph nodes harvested in colon cancer.


RESUMO Fundamento: O limite atual para a coleta mínima de linfonodos pode não ser adequado para o estadiamento adequado no câncer de cólon e novas técnicas cirúrgicas podem permitir que um número maior de linfonodos seja coletado. O objetivo deste estudo foi examinar o papel prognóstico da coleta e exame de linfonodos em número maior do que o limite recomendado (≥ 12), em pacientes com câncer de cólon. Método: Este estudo retrospectivo incluiu 179 pacientes submetidos à ressecção aberta de cólon para adenocarcinoma de cólon. A ressecção D3 com ligadura vascular alta foi realizada para que um grande número de linfonodos fosse removido na maioria dos pacientes. As diferenças na sobrevida global entre abaixo e acima de três pontos de corte (≥ 18, ≥ 24, ≥ 40) foram estimadas. Resultados: Durante a mediana de 33 meses de seguimento, 45 pacientes morreram e a sobrevida global média foi de 108,7 ± 5,6 meses (IC 95%: 97,7-119,7). O número médio de linfonodos coletados e examinados foi de 44,0 ± 25,7 (mediana = 38; variação: 7-150). Nenhum efeito significativo foi encontrado para três valores de corte diferentes (≥ 18, ≥ 24 ou ≥ 40 linfonodos) na sobrevida global média (p >0,05 para todas as comparações). O mesmo foi verdadeiro para toda a população do estudo, bem como para os subgrupos de pacientes N0 (N negativos) e N1-2 (N positivos), quando analisados separadamente. Conclusões: Nossos achados não apoiam o benefício na sobrevida de um número substancialmente maior de linfonodos coletados no câncer de cólon.


Subject(s)
Humans , Male , Female , Adenocarcinoma/diagnosis , Colonic Neoplasms/diagnosis , Colonic Neoplasms/mortality , Lymph Node Excision/methods , Prognosis , Survival Analysis
18.
Int. j. morphol ; 38(5): 1479-1484, oct. 2020. tab, graf
Article in English | LILACS | ID: biblio-1134465

ABSTRACT

SUMMARY: Gastric cancer (CG) is the second leading cause of cancer deaths. The best treatment option for patients with advanced GC (AGC) is still surgery, which involves performing a gastrectomy and D2 lymphadenectomy (D2L). The aim of this study was to determine postoperative morbidity (POM) and 5-year OS in patients resected by AGC without neoadjuvant. Case series with follow-up of patients with AGC undergoing total or subtotal gastrectomies and D2L, consecutively at RedSalud Mayor Temuco Clinic, between 2008 and 2019. The outcome variables were POM and 5-year OS. Other variables of interest were surgical time, number of resected lymph nodes, hospital stay, and recurrence. Descriptive statistics was used, and Kaplan-Meier curves were calculated. In this analysis 38 patients (71.1 % men), with a median age of 65 years, were operated. The most frequent location was subcardial (50.0 %). The most frequent type of resection was total gastrectomy (60.5 %). The median of surgical time, number of resected lymph nodes and hospital stay; was 190 min, 32 and 6 days respectively. MPO was 18.4 %. With a median follow-up of 28 months, a recurrence of 44.7 % was verified; and 5-year OS for stages IIIA, IIIB and IV were 53.3 %, 46.1 % and 20.0 % respectively (p= 0,007). The results achieved, in terms of POM and OS series were similar to national and international series in which neoadjuvant therapies have not been applied.


RESUMEN: El cáncer gástrico (CG) es la segunda causa de muerte por cáncer. La mejor opción terapéutica para pacientes con CG avanzado (CGA), sigue siendo la cirugía, que supone la realización de gastrectomía asociada a linfadenectomía D2 (LD2). El objetivo de este estudio fue determinar morbilidad postoperatoria (MPO) y supervivencia (SV) en pacientes resecados por CGA sin neoadyuvancia. Serie de casos con seguimiento, de pacientes con CGA sometidos a gastrectomía total o subtotal con LD2, de forma consecutiva, en Clínica RedSalud Mayor Temuco, entre 2008 y 2019. Las variables resultado fueron MPO y SV actuarial global (SVAG) a 5 años. Otras variables de interés fueron: tiempo quirúrgico, número de linfonodos resecados, estancia hospitalaria y recurrencia. Se utilizó estadística descriptiva, con medidas de tendencia central y dispersión; y análisis de SV con curvas de Kaplan Meier. Se intervinieron 38 pacientes (71,1 % hombres), con una mediana de edad de 65 años. La localización más frecuente fue subcardial (50,0 %); el tipo de resección más frecuente fue gastrectomía total (60,5 %). Las medianas del tiempo quirúrgico, del número de linfonodos resecados y de estancia hospitalaria; fue 190 min, 32 y 6 días respectivamente. La MPO fue 18,4 %. Con una mediana de seguimiento de 28 meses, se verificó recurrencia de 44,7 %; y SVAG a 5 años para estadios IIIA, IIIB y IV de 53,3%, 46,1 % y 20,0 % respectivamente (p=0,007). Los resultados obtenidos, en términos de MPO, mortalidad y SVAG, fueron similares a series de centros de derivación nacionales e internacionales en los que no se ha aplicado terapias neoadyuvantes.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Stomach Neoplasms/surgery , Gastrectomy/methods , Lymph Node Excision/methods , Postoperative Complications , Recurrence , Survival Analysis , Follow-Up Studies , Operative Time , Length of Stay
19.
Appl. cancer res ; 40: 1-6, Oct. 19, 2020. ilus, tab
Article in English | LILACS, Inca | ID: biblio-1282611

ABSTRACT

Background: Oral squamous cell carcinoma (OSCC) is the most frequently occurring malignant tumor of the head and neck region. Chk2 (Checkpoint kinase 2) is considered a tumor suppressor gene that acts on the cellular response to DNA damage. However, the role of Chk2 in OSCC prognosis is not yet fully understood. The objective of this study was to evaluate Chk2 immunoexpression in OSCC and to elucidate the association between its expression and clinicopathological parameters of prognostic importance, including overall survival, disease-free survival, and metastasis-free survival. Methods: Chk2 expression was analyzed in 101 samples from patients with OSCC using immunohistochemistry. We stratified the patients into high expression (> 66% of cells positive for Chk2) and low expression (< 66%) groups. Results: Chk2 showed high expression in 57.43% of OSCC. In our study, the expression of Chk2 did not correlate with any of the prognostic parameters evaluated. There was no difference between overall survival, metastasis-free survival, and disease-free survival according to Chk2 expression. Conclusion: Despite the great importance of Chk2 in the development of different types of cancer, our findings do not favor Chk2 as a prognostic marker in oral squamous cell carcinoma.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Mouth Neoplasms/metabolism , Immunohistochemistry , Carcinoma, Squamous Cell/metabolism , Checkpoint Kinase 2/metabolism , Prognosis , Survival Analysis
20.
Rev. chil. cardiol ; 39(2): 122-132, ago. 2020. tab, graf
Article in Spanish | LILACS | ID: biblio-1138525

ABSTRACT

OBJETIVO: Describir los resultados inmediatos y alejados de la cirugía coronaria sin circulación extracorpórea (CEC) y comparar los resultados de la estrategia de indicación de la técnica en dos períodos. PACIENTES Y MÉTODOS: Estudio retrospectivo de 428 pacientes intervenidos de cirugía coronaria sin CEC entre 2004 y 2019 en el Hospital Guillermo Grant Benavente. Se dividen en Grupo 1, período 2004-2008 (N=216) y Grupo 2, período 2009-2019 (N=212). Se estudiaron sus características clínicas, resultados quirúrgicos, morbi-mortalidad operatoria y eventos adversos al 31 de junio de 2019 y se compararon los resultados de los grupos a 5 años. RESULTADOS: No hubo diferencias en la distribución por sexo, edad, factores de riesgo y patologías asociadas entre los grupos. Hubo diferencias en las lesiones coronarias entre los Grupos 1 y 2: lesión de un vaso en 45 (20,4%) versus 125 (59%) y tres vasos en 75 (34,5%) versus 19 (9%) respectivamente (p<0,001). El riesgo operatorio por EuroSCORE logístico fue 3,3±3,95 versus 5,4±7,7 (p<0,001). Se confeccionaron 2,3±0,9 anastomosis distales en el Grupo 1 versus 1,3±0,6 en Grupo 2 (p<0,001). La tasa de complicaciones fueron 17,6% en el Grupo 1 y 5,7% en el 2 (p<0,001). La mortalidad operatoria globral fue 4 pacientes (0,9%). El seguimiento comprendió 9,2±3,8 años. La sobrevida a 10 años fue 76,9% y tasa de eventos cardiovasculares mayores 37,6%. No hubo diferencia entre los grupos a los 5 años. CONCLUSIONES: La selección de pacientes con anatomía más favorables o de mayor riesgo operatorio tuvo tasas de sobrevida y eventos similares a los observados con la estrategia menos selectiva a 5 años de seguimiento.


AIM: To describe the immediate and long-term results of off pump coronary artery surgery without cardiopulmonary bypass (OPCABG) comparing the results observed in two consecutive periods. PATIENTS AND METHODS: A retrospective study of 428 patients undergoing OPCABG between 2004 and 2019 at the Guillermo Grant Benavente Hospital. Group 1 patients operated between 2004 - 2008 (N = 216) and Group 2 operated between 2009 and 2019 (N = 212). RESULTS: There were no differences in sex, age, risk factors and co morbidities between groups. There were differences in the number of coronary lesions between groups: one vessel disease in 45 (20.4%) versus 125 (59%) and three vessels in 75 (34.5%) versus 19 (9%) in Group 1 vs Group 2, respectively (p <0.001). The operative risk for logistic EuroSCORE was 3.3 ± 3.95 in Group 1 versus 5.4 ± 7.7 in Group 2 (p <0.001). 2.3 ± 0.9 distal anastomoses were performed in Group 1 compared to 1.3 ± 0.6 in Group 2 (p<0.001). Adverse events occurred in 17.6% o patients in Group 1 compared to 5.7% in Group 2 (p<0.001). Overall, 4 patients died (0.9%). Mean overall survival at 10 years was 76.9% and the rate of major cardiovascular events was 37.6%, no differences being observed between groups. CONCLUSIONS: At 5 years of follow-up the selection of patients with more favorable anatomy or greater operative risk had similar survival rates and events than those observed with the least selective strategy.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Coronary Disease/surgery , Coronary Artery Bypass, Off-Pump/methods , Postoperative Complications/epidemiology , Time Factors , Survival Analysis , Retrospective Studies , Risk Factors , Follow-Up Studies , Cause of Death , Treatment Outcome , Coronary Artery Bypass, Off-Pump/mortality
SELECTION OF CITATIONS
SEARCH DETAIL